Moderna Closes Lower After Early Disclosure of Personalized Cancer Vaccine Data 17.57%，AI Major Players Step Up Life Sciences Investment

Article

Biotechnology News Summary: Moderna Faces a “Sell-the-News” Sell-off,AI Major Players Continue to Invest in Life Sciences

BlockBeats reported that October 23, Moderna faced a sell-off after data from its Phase personalized cancer vaccine trial was disclosed ahead of schedule. According to BIT(bit.com) market data,October 22, its stock closed down 17.57%, at 202.63 USD, after touching a session low of 180.80 USD, down approximately 26.45%. Previously,August 19, news of positive trial results had driven its stock up sharply by 177%。

It is worth noting that this disclosure did not indicate a trial failure. Merck & Co. and Moderna subsequently announced that,INTerpath-001 in the Phase trial, the personalized therapy intismeran combined with Keytruda reduced the risk of recurrence or death in certain patients with postoperative melanoma by 42%, and reduced the risk of distant metastasis or death by 38%. Overall survival data are not yet mature, and the study is ongoing. Analysts believe the stock decline was a “sell-the-news” reaction following a sustained rise.

In addition,AI major players continue to invest in life sciences. OpenAI announced on October 20 that it had acquired Orchestra Bio, which develops a AI platform to help biopharmaceutical teams coordinate drug development. Its team and technology will be integrated with OpenAI’s life sciences tool Rosalind. The transaction value was not disclosed. OpenAI also said it has partnered with Moderna and Novo Nordisk to apply AI to research and development workflows.

Anthropic previously also acquired AI biotech company Coefficient Bio. The transaction was reportedly valued at approximately 400000000 USD, payable in shares. According to a Reuters September report, Anthropic has established an internal biology laboratory. Its head of life sciences said that, measured by personnel and resource investment, life sciences has become one of the company’s largest areas of investment. This should be distinguished from “business resource investment” and “single-transaction investment value”; it cannot currently be concluded that this was its largest investment.

Nvidia announced on October 21 that it had jointly launched an open model,RFD4-Proteina with the University of Washington’s Institute for Protein Design, for protein design and search. Companies including Benchling, Boltz, Danaher, and Automata are also using its BioNeMo platform to develop scientific AI agents that connect drug design, biological data, and automated laboratory workflows.

In large pharmaceutical M&A, according to October 19 company announcements, Germany’s Merck (Merck KGaA) has signed an agreement to acquire 20 USD for cash at RNA per American depositary share, representing a premium of October 16 to its 130%closing price. The transaction implies an equity value of approximately 1300000000 USD and is expected to close in the first quarter of 2027, subject to shareholder, court, and regulatory approvals. Germany’s Merck and U.S. Merck, Moderna’s partner, are different companies.

Key points

Moderna October 22 Stock Closes Lower 17.57%, at 202.63 USD, after touching a session low of 180.80 USD。
INTerpath-001 The Phase trial showed that intismeran combined with Keytruda could reduce the risk of recurrence or death in certain patients with postoperative melanoma by 42%, and reduce the risk of distant metastasis or death by 38%。
Overall survival data are not yet mature, and the study is ongoing.
OpenAI announced the acquisition of Orchestra Bio. The transaction value was not disclosed, and its team and technology are planned to be integrated with the life sciences tool Rosalind.
Anthropic acquired Coefficient Bio. The transaction was reportedly valued at approximately 400000000 USD, payable in shares.
Nvidia and the University of Washington’s Institute for Protein Design launched an open model RFD4-Proteina。
Germany’s Merck KGaA plans to acquire Silence Therapeutics for cash at 20 USD per American depositary share, implying an equity value of approximately 1300000000 USD, subject to shareholder, court, and regulatory approvals.

AI-assisted interpretation

The following is analysis, separate from reported facts. Verify important claims independently.

This set of information covers multiple life sciences events: Moderna’s share price fell after rising sharply earlier, due to the early disclosure of Phase data, but the disclosure did not indicate that the trial had failed; OpenAI, Anthropic, and NVIDIA continued advancing their life sciences-related businesses; and Germany’s Merck KGaA proposed acquiring Silence Therapeutics.

Why it matters to readers

It also reflects the impact of biopharmaceutical clinical data on stock prices, as well as the continued investment by artificial intelligence companies and major pharmaceutical companies in life sciences.

A distinction must be made between a “share price decline” and “trial failure”: the article stated that Moderna’s trial results remained positive, but overall survival data were not yet mature. An acquisition transaction also does not mean that it has already been completed.

Risks and unknowns

Overall survival data for Moderna’s personalized cancer vaccine were not yet mature.
The consideration for OpenAI’s acquisition of Orchestra Bio was not disclosed, and the evidence did not state whether the transaction had been completed.
Anthropic's acquisition of approximately 400000000 USD The amount is based on reported content; the evidence does not provide the original transaction announcement.
Silence Therapeutics’ acquisition still requires approval from shareholders, the court, and regulators.

Moderna Closes Lower After Early Disclosure of Personalized Cancer Vaccine Data 17.57%，AI Major Players Step Up Life Sciences Investment

Article

AI-assisted interpretation

Why it matters to readers

Risks and unknowns

Related Developments

Related concepts

Keep following

Security Center